Postdoctoral PDDM900 ⭐ 2 Credits Semester 1

Program Launch Studio: Site Scope, Asset Verification, Partner Qualification, and the Intake-to-Release Dossier

This course establishes the factual baseline for the OTC dermatological semisolids program before any formulation, purchase or permit decision is made. Skipper re-applies the PDQC800 site-and-asset audit method, aimed now at nonsterile topical manufacture, and does not re-teach it. Asset verification: - Physically verify every asset at the Peptide Partners site: 3x Agilent 1260 HPLC-DAD, the triple-quad LC-MS/MS, and bioMérieux BacT/ALERT. - Identify the unlisted second mass spectrometer from its nameplate, serial number, software and ion source, and determine what it can do. If it is a GC-MS, volatile extractables and possibly headspace residual-solvent work could stay in-house. - Confirm or refute the assumed bench assets: balances, pH meter, centrifuge, ultrasonic bath, ovens, refrigerators, incubators and BSC. - Score each asset against the 20-row semisolid release/stability matrix from the technical brief. - Record that BacT/ALERT is a qualitative time-to-detection sterility system. It cannot produce the cfu counts that USP <61> enumeration needs, or the log reductions that USP <51> needs. Material inventory and permits: - Inventory all materials on site: peptide APIs, reference standards, and any prescription drug substances or products. - Tie that inventory to Florida permit consequences. The OTC drug manufacturer permit under §499.01(2)(n) prohibits possessing or purchasing prescription drugs. Legal and regulatory scope: - Map legal entities (Peptide Partners, Pirsek), addresses, establishment DUNS numbers and activities (manufacture, package, relabel, distribute, cosmetic) for regulatory counsel. - Cover FDA registration and listing, labeler code, the OMUFA MDF vs CMO facility fee, the MoCRA §364i drug-cosmetic exemption, and the Florida ch. 499 permit and §499.015 product-registration triggers. - Run a documented field-research task on the items the regulatory brief marks [unverified]: DBPR application and inspection practice, and 61N-1 FAC. Partner pre-qualification: - Pre-qualify contract labs and CMOs so outsourced work can start in semesters 2–3. This covers: - microbiology: <61>/<62>/<60>/<51> with semisolid method suitability; - ICH Q1A(R2) stability storage, including the low-RH condition for semi-permeable packs; - residual solvents, elemental impurities, benzene, KF, rheology and E&L; - bridge manufacturing. - Screen candidates against recent OTC topical warning-letter themes: §211.84(d) identity testing, §211.192 OOS investigations, §211.165(b) objectionable organisms, and water-system Bcc. Bench kit and program artifacts: - Make an evidence-based decision on the minimum bench kit: jacketed vessel, overhead stirrer, rotor-stator probe homogenizer, circulating bath, and pH meter with spear electrode. - Create the two artifacts that every later course populates: the applicability register and the longitudinal intake-to-release dossier skeleton. The course is API-agnostic, contains no dosing or clinical guidance, and is not legal advice. Regulatory conclusions are framed as questions for counsel.

📅 Studied by Skipper on 2026-10-16

📖 Core Concepts

Claude Opus 5.5

Core Concepts: Program Launch Studio

Site Scope, Asset Verification, Partner Qualification, and the Intake-to-Release Dossier (PDDM900)

1. What This Course Is About

Skipper, every course you have taken so far taught you how to know things about molecules: how to measure them, separate them, sequence them, and prove a method measures what it claims to. PDDM900 asks you to apply the same rigor to the organization itself. Before Peptide Partners can make one tube of OTC cream, someone has to answer some plain questions with evidence. What do we own? What does each item actually do? Who are we legally, and at which address? Which rules apply to us, and why? Which tests can we run ourselves, and which go to a partner whose competence we have checked?

This is a course about epistemics under regulation. The lab bench of PDQC800 becomes the whole enterprise. The output is not a product. It is a set of controlled documents that later courses (PDDM901–925) and the PDDM999 capstone will rely on. If these documents are wrong, every later decision inherits the error. An asset register that says "pH meter: yes" when the meter has no spear electrode and no calibration record is like a mislabeled reference standard: every downstream result is quietly wrong.

The governing analogy for this course is a surveyor's work before a building goes up. The architect (PDDM903 formulation, PDDM921 process) cannot design safely until someone has walked the land, set the boundary markers, recorded the easements, tested the soil, and marked every claim on the plat as surveyed, taken from a deed, or hearsay. PDDM900 is the survey.

Three things make this harder than PDQC800, and more interesting:

  • The products are unknown. The dermatologist's formulas have not arrived. Every artifact must be API-agnostic, which means built from triggers ("if the vehicle contains water…", "if a component is glycerin…") rather than from facts about a specific product.
  • The matrix is new. You know peptide solutions and lyophilized powders. Emulsions, ointments and gels are thermodynamically metastable, multiphase, lipid-rich, and (when they contain water) able to grow microbes. That changes almost every test.
  • The legal topology is new. OTC monograph drugs (FD&C Act §505G; 21 CFR 330.1), Florida ch. 499 permits, OMUFA fees and MoCRA create a map where permissions attach to activities at addresses performed by entities. A peptide reference standard in the wrong freezer can become a permit problem.

The program boundary is part of the science, so state it every time: manufacture and package OTC monograph-conforming creams, ointments, lotions and gels from dermatologist-specified formulas. Rx/NDA products are out of scope. This course gives no dosing or clinical guidance, and nothing here is legal advice. Legal interpretations are framed as questions for counsel, never as conclusions.


2. Principle One: Fact-First Scoping and the Confidence-Tag Discipline

Every claim in every program artifact carries one of three tags. The tag is a mandatory field, not decoration.

  • [verified-primary]: confirmed against the originating source. Examples: the instrument nameplate photographed on site, the current eCFR text retrieved on a recorded date, the Florida Statutes on the Legislature's official site, a signed calibration certificate, or a DBPR written reply.
  • [verified-secondary]: confirmed against a reliable but derivative source. Examples: a vendor brochure, a trade-association summary, a consultant memo, an older printed textbook, or a colleague's recollection backed by a purchase order.
  • [unverified]: believed, assumed, inherited from a brief, or unknown. Examples: "the second MS is probably a GC-MS," the exact content of 61N-1 FAC, or the OMUFA fee amounts until checked against the Federal Register notice.

The rule that gives the tags force:

Gate G may close  ⇔  for every row r required by G:
        status(r) = closed
    AND tag(r) ∈ {verified-primary}
        (or verified-secondary with a written justification
         accepted by the gate owner)
    AND evidence_pointer(r) resolves to a retrievable, ALCOA+ record

Corollary: one [unverified] row on the critical path → gate stays open.

Why this is subtle. The tag is a property of the claim-source pair, not of the claim. "The 1260 has a G7129 vialsampler" is [verified-secondary] from a purchase order and becomes [verified-primary] only when you photograph the module label. Tags also decay. A regulation retrieved 18 months ago is no longer primary evidence of current text if an amendment has issued. That is why every register row has a retrieval date and a next-review date. This is the data-integrity logic of PDQC801 (attributable, contemporaneous, original) applied to regulatory and organizational facts.

Several numbers in this program's brief (OMUFA FY2027 fees and due dates, the 12-digit NDC effective date, the 64B16-27.700 FAC amendment date, M020 sunscreen order dates, the Unified Agenda timing for the MoCRA GMP NPRM) arrive to you as brief-sourced. Treat them as [unverified] until you retrieve the primary document. Doing so is the course's first exercise in discipline.


3. Principle Two: Ownership Is Not Capability. Asset Verification as Organizational Metrology

PDQC805 taught you that an instrument is usable for GMP work only when it is qualified (IQ/OQ/PQ), calibrated, under change control, and running software with Part 11-compliant controls. PDDM900 adds a fourth factor: fit to the semisolid matrix and the test's intended use. Capability is a logical AND, not a sum:

Capability(asset, test) = H ∧ Q ∧ S ∧ M

  H = hardware present and positively identified
      (model, serial, modules, firmware)
  Q = qualification + calibration current for the intended operating range
  S = software/CDS version validated; audit trail, access, e-records controls
      (PDQC814)
  M = matrix and intended-use suitability
      (e.g., sample prep, detector, source, quantitative vs qualitative)

If any term = 0 → the test row is NOT "in-house now."

The audit method carries over from PDQC800. You use a walk-down checklist, photographs of nameplates and module labels, and a cross-check of each physical item against purchase records, calibration certificates and qualification files. For the three Agilent 1260 Infinity HPLC-DAD systems, record pump type (binary or quaternary, which matters for gradient flexibility with lipophilic actives), column-oven range, whether the autosampler is thermostatted (relevant for labile actives and preservatives in extracted samples), DAD spectral range, and CDS version with its qualification and Part 11 status.

The second MS is an unknown to be resolved, not a missing detail. The identification protocol is: nameplate model and serial → inlet (LC or GC) → analyzer (quadrupole, ion trap, TOF, Orbitrap) → software → ion sources → any headspace (HS) or thermal-desorption sampler → vendor service record. Then apply the decision tree:

  1. If GC-MS: it may support volatile extractables. It supports USP <467> residual solvents only if headspace sampling is present or added, and the method still needs validation or verification. It is a candidate for benzene screening on carbomer components and benzoyl-peroxide-risk products (FDA benzene alerts; FDA guidance on reformulating carbomer products manufactured with benzene, Dec 2023).
  2. If LC-HRMS (TOF/Orbitrap): it supports structural identification of leachables and degradants, which complements the triple quad's targeted quantitation.
  3. If neither, or if hardware exists without qualification or software controls, those needs go on the outsource list.

The capability memo must also list residual gaps that exist whatever the second MS turns out to be: ICP-OES/ICP-MS for <232>/<233>, Karl Fischer (<921>), and GC-HS if it is not present. Stating what remains missing is as important as stating what was found. A memo that lists only the positives misleads its reader.

The triple-quad and APCI. ESI works best for analytes that are already charged or easily protonated in solution, such as peptides. Many semisolid analytes are neutral and lipophilic: fatty-alcohol degradants, some preservatives, antioxidants such as BHT, and nonvolatile leachables from laminate tubes. Atmospheric-pressure chemical ionization vaporizes the eluent and ionizes in the gas phase by proton transfer from corona-generated reagent ions, so it reaches analytes ESI handles poorly. Whether the triple quad has an APCI source is therefore a capability question with real consequences. Record it [verified-primary] from the source housing label, not from memory.


4. Principle Three: Qualitative vs Quantitative Is a Category Boundary. The BacT/ALERT Lesson

The clearest example of a capability mismatch in this program is the bioMérieux BacT/ALERT. It detects microbial growth by CO2-driven colorimetric change in a sealed bottle and reports time to detection, which is a presence/absence answer. That makes it a strong tool for rapid sterility-type testing, which you studied in PDQC822. It is the wrong kind of measurement for nonsterile products:

  • USP <61> requires enumeration: total aerobic microbial count (TAMC) and total combined yeasts and molds count (TYMC) in cfu/g.
  • USP <51> requires log-reduction counts at defined time points.
  • Using it for <62>-type specified-organism detection would make it an alternative method, which requires validation under <1223>. That includes showing equivalence for the specific organisms and matrix, and it is not a shortcut.

Fit statement for the asset register: "BacT/ALERT: qualitative CO2 time-to-detection system. Not suitable for <61> TAMC/TYMC or <51> enumeration. Any <62> use requires <1223> validation. Retained for future sterile peptide work." The general point is that a method's output type (binary, ordinal, continuous) must match the acceptance criterion's type. You cannot get a count from a yes/no instrument, just as you cannot get an assay value from an identity test.

Worked example: reading <1111> cutaneous criteria correctly

For nonaqueous and aqueous preparations for cutaneous use, USP <1111> gives TAMC 102 cfu/g, TYMC 101 cfu/g, and absence of Staphylococcus aureus and Pseudomonas aeruginosa in 1 g. The counterintuitive part is the interpretation clause in <1111> (verify current wording):

Acceptance criterion 10^1 cfu/g → maximum acceptable count = 20 cfu/g
Acceptance criterion 10^2 cfu/g → maximum acceptable count = 200 cfu/g

Example: TAMC = 150 cfu/g, TYMC = 18 cfu/g → conforms
         TAMC = 210 cfu/g                 → does not conform

A contract lab that reports "fail" at 150 cfu/g against "102" has misread the chapter. Probe for this during pre-qualification.

Worked example: <51> Category 2 log reduction

Topically applied, aqueous-based products fall in <51> Category 2. Bacteria require a ≥2.0 log reduction from the initial count at 14 days and no increase from the 14-day count at 28 days. Yeasts and molds require no increase from the initial calculated count at 14 and 28 days. "No increase" is defined as not more than 0.5 log10 higher than the comparison value (verify current text).

LR(t) = log10(N0) − log10(Nt)

N0  (calculated initial)  = 5.5 × 10^5 cfu/g  → log = 5.74
N14                       = 2.1 × 10^3 cfu/g  → log = 3.32   LR14 = 2.42 ≥ 2.0  ✓
N28                       = 4.0 × 10^3 cfu/g  → log = 3.60   Δ(28 vs 14) = +0.28 ≤ 0.5  ✓

The arithmetic is simple. The validity of Nt is not. If the neutralizer does not quench the preservative (parabens, phenoxyethanol, organic acids) and the surfactants in the recovery diluent, preservative carried into the plate keeps killing organisms. The lab then reports a large LR for a product that may be poorly preserved. This is why method suitability with neutralizer-efficacy and recovery data in emulsions and ointments is the central question in Week 8, not a side question.


5. Principle Four: The Matrix Changes Everything. What Carries Over and What Does Not

The PDQC sequence gave you a full quality toolkit, and most of it transfers directly: QMS architecture, data integrity, analytical procedure lifecycle and validation statistics (PDQC802), OOS investigation under 21 CFR 211.192, stability statistics, and QC microbiology concepts. What changes is the physics and biology of the sample.

Dimension Peptide QC (PDQC) OTC semisolid (PDDM)
Sample state Solution or lyophilizate; dissolves cleanly Multiphase emulsion, ointment, or gel; analyte partitions between phases; extraction recovery is the key validation risk
Microbial risk Sterility and endotoxin (parenteral) Bioburden, specified organisms, Burkholderia cepacia complex (<60>), preservative efficacy; water is the main risk driver
Physical attributes Aggregation, higher-order structure Rheology, yield stress, globule size, polymorphism of the API or excipients, phase separation, uniformity within the container
Packaging Glass vials, CCI Laminate or plastic tubes, jars, airless pumps; often semi-permeable (water loss); fill-and-seal
Regulatory frame Rx/BLA/NDA-like OTC monograph (§505G; 21 CFR 330.1), Drug Facts (21 CFR 201.66), Florida OTC permit

Microstructure is part of the product's identity. [Chang et al., 2013a] and [Chang et al., 2013b] describe topical "sameness" at three levels. Q1 is the same components. Q2 is the same amounts. Q3 is the same arrangement of matter: globule size distribution, rheology, polymorphic form of the dispersed drug, pH, specific gravity, and drug release rate. Two creams with identical ingredient lists can perform differently because the process gave them different microstructures. This is why the 20-row test matrix includes viscosity, microscopy, specific gravity and IVRT alongside assay. It is also why manufacturing parameters such as homogenizer tip speed, cooling rate and phase-addition order become critical process parameters later (PDDM921/991). [Buhse et al., 2005] make the related point that even the dosage-form name (cream, ointment, lotion, gel) should follow from measurable attributes such as water and volatiles content, hydrocarbon/wax/polyol content, and viscosity, not from marketing. Check the exact decision-tree thresholds against the paper before using them in PDDM901.

Worked example: water loss in semi-permeable packaging

ICH Q1A(R2) treats aqueous products in semi-permeable containers specially: low-RH conditions (e.g., 25 °C/40% RH or 30 °C/35% RH) and a 5% water loss from initial counted as significant change under defined conditions. Q1A(R2) also allows the water-loss rate at an alternative RH to be converted using a ratio. Verify the exact table and the §2.2.7.3 wording, and track the consolidated ICH Q1 revision.

Ratio of water-loss rates (same temperature) = (100 − RH_alt) / (100 − RH_ref)

Example: measured at 60% RH, reference 25% RH
  ratio = (100 − 60)/(100 − 25) = 40/75 = 0.53
  → water loss at 25% RH ≈ (measured loss at 60% RH) / 0.53
  e.g., 1.8% observed at 60% RH → ≈ 3.4% predicted at 25% RH

The driving force for vapor transmission through the tube wall is the humidity deficit outside, so drier storage removes water faster. This is Fick's law, which you met in PHYS201 and CHEM301, appearing as a stability-chamber requirement. It also explains why a contract stability lab offering only 25/60, 30/65 and 40/75 chambers may not meet your needs.


6. Principle Five: Regulatory Topology. Entity × Address × Activity × Product Class

Regulatory obligations attach to tuples, not to "the company." The scope memo is a matrix with one row per (entity, physical address, activity, product class). Each row records the establishment's site-specific DUNS (not the corporate headquarters DUNS) and the triggered obligations.

Obligation set O = f(entity, address, activity, product_class, seller_relationship)

activity      ∈ {manufacture, package, label/relabel, distribute, test-only, cosmetic manufacture}
product_class ∈ {OTC monograph drug, drug-cosmetic, pure cosmetic, Rx (out of scope)}

Federal layer (verify each against current eCFR and statute):

  • Registration and listing: register within 5 calendar days of beginning operations, update annually from Oct 1 to Dec 31, list every commercially distributed drug, and submit in SPL format (21 CFR 207.17, 207.21, 207.41). 207.33 governs NDC format. The NDC labeler code belongs to the firm that markets the product, which may be the brand owner rather than the manufacturer. "Distributed by" or "Manufactured for" statements follow 21 CFR 201.1. The 12-digit NDC final rule changes format going forward (brief-sourced effective date 2033-03-07, [unverified]).
  • OMUFA (21 USC 379j-71/72): a facility is assessed as a Monograph Drug Facility (MDF) or at the lower Contract Manufacturing Organization (CMO) rate, depending on whether the owner or an affiliate sells the products directly. The brief gives FY2027 figures and two due dates. Treat them as [unverified] until checked against the Federal Register fee notice. Failure to pay puts the facility on an arrears list, and products from an arrears-listed facility are deemed misbranded under §502(ff). One unpaid invoice can make every product misbranded.
  • MoCRA: the §364i exemption covers products regulated as drugs. If the same facility also makes pure cosmetics, §364c facility registration and product listing are triggered (subject to the §364h small-business exemption). A drug-cosmetic (e.g., a moisturizer with a monograph sunscreen active) is regulated under the drug pathway. Mixed portfolios create mixed obligations.
  • §760 (21 USC 379aa): the "responsible person" named on the label must handle serious adverse-event reporting for nonprescription drugs. That role is usually the brand owner.

Florida layer. §499.003 defines "manufacture" broadly enough to include "compounding." The pharmacy-compounding framework (§465.003; Rule 64B16-27.700 FAC; federal 21 USC 353a/353b) applies only to licensed pharmacies and outsourcing facilities. It is a contrast, not a pathway. Note that 64B16-27.700 has a brief-sourced amendment date of 2026-08-03 that needs verification. The §499.01(2) permit map includes (n) OTC drug manufacturer, (p) cosmetic manufacturer (with brief-stated exemptions at ≤$25,000 sales or relabel-only; verify), and (a) prescription drug manufacturer, plus repackager and distributor permits. Fees fall under §499.041. §499.015 requires biennial registration of each drug manufactured, packaged or labeled in Florida, and unregistered products are exposed to seizure. Rule chapter 61N-1 FAC content is [unverified] and is the focus of the Week 6 field research, which uses primary sources, a dated contact log, and screenshot or PDF capture.

The counterintuitive consequence: the peptide freezer. According to the brief, the OTC manufacturer permit under §499.01(2)(n) prohibits possessing or purchasing prescription drugs. Peptide Partners holds peptide APIs, research peptides, reference standards and client samples. Whether any of these count as "prescription drugs" under Florida law is a question for counsel. The analyst's job is to produce the inventory (source, status, quantity, location), describe the segregation options, and state what evidence each option would need:

  1. A separate legal entity and/or separate premises (evidence: lease, floor plan, access control, separate permits).
  2. Obtaining an Rx manufacturer permit (evidence: application, GMP readiness for that scope).
  3. Transfer of materials off-site (evidence: chain-of-custody and reconciliation records).
  4. Reclassification as reference standards, if counsel and DBPR agree that is legally meaningful (evidence: written interpretation, plus use, quantity and labeling controls).

You present these options. You do not choose among them. This separation between technical facts and legal judgment is the professional discipline the course is building.


7. Principle Six: You Can Delegate Tasks, Not Accountability

[Sharp, 2005] argues throughout that GMP rules make sense once you see their rationale: each rule closes a specific path by which a patient could receive the wrong, contaminated or substandard product. Responsibility splits in contract manufacturing follow the same logic. Each path must have exactly one owner who cannot hand it off.

  • The facility (whoever physically manufactures) registers, pays OMUFA (at the CMO rate if it does not sell), and owns cGMP compliance for its operations.
  • The brand owner holds the labeler code, is named under 21 CFR 201.1, and is typically the §760 responsible person.
  • The Quality Unit duties of 21 CFR 211.22 (approve or reject components, in-process materials, finished product, procedures and specifications, and review production records) are not delegable to a contractor in a way that removes the owner's responsibility. The precise scope of 21 CFR 200.10(b) on contract facilities as extensions of the manufacturer must be checked against current text. FDA's quality-agreement guidance for contract manufacturing arrangements (verify title and status) frames the written allocation of duties.
  • Consultants under 21 CFR 211.34 must have documented qualifications, and records must show the scope of their advice. Hiring a consultant does not transfer QU judgment. Week 10 asks you to study how inadequate use of consultants appeared in an FDA citation (the Columbia Cosmetics letter named in the brief; retrieve and read the primary letter).

Analogy: a quality agreement is a wiring diagram, not a contract of indemnity. Its value is that every requirement (component testing, deviation handling, OOS notification, change control, release) connects to exactly one named terminal. A requirement wired to "both" without a defined handoff is effectively wired to nobody.

Recurring warning-letter themes as a screening lens. The brief points to recurring OTC and topical citations:

  • §211.84(d): no identity testing on each component lot, or reliance on a certificate of analysis without validating the supplier.
  • §211.192: inadequate investigations.
  • §211.100(a): no validated process.
  • §211.165(b): no appropriate microbial testing of finished product.
  • §211.22: QU failures.
  • Water systems contaminated with Burkholderia and Pseudomonas.

These form a pattern because small OTC topical makers often underestimate water as a microbial risk. Purified water in a nonsterile, water-containing cream is effectively an ingredient that can grow organisms. FDA's draft guidance Microbiological Quality Considerations in Non-Sterile Drug Manufacturing (Sept 2021) gives the rationale, and the Bcc-specific attention in <60> follows from it.


8. Principle Seven: Partner Qualification Is a Ladder, Probed at the Matrix

Qualification proceeds through statuses, and the status is always recorded:

questionnaire → document review → audit (remote/on-site) → quality agreement → approved supplier list
   (claims)        (evidence)        (observation)            (obligations)        (permission to use)

Do not skip a rung. A lab that "does <61>" in its brochure is at rung 0. What separates real competence from listed scope is matrix-specific questioning:

  • Microbiology (Week 8): method-suitability experience with emulsions and ointments. Ask how they disperse lipid samples (isopropyl myristate, polysorbate 80, warming limits), how they choose and demonstrate neutralizers, and what recovery acceptance they use. For Bcc, ask about selective media (BCSA), the identification method, and experience with isolates from water systems. Ask about chain of custody and hold times validated for transit from Sarasota.
  • Chemistry and stability (Week 9): ICH Q1A(R2) conditions plus low-RH chambers. Ask about Q1B photostability (≥1.2 million lux·h; ≥200 W·h/m² near-UV). Confirm they can run <467>, <232>/<233> with ICH Q3D(R2) cutaneous PDEs (Appendix 5; verify applicability), KF, rheometry and yield stress, XRPD/DSC, E&L volatiles and elementals, and benzene in carbomer (the ICH Q3C benzene limit of 2 ppm is the reference value for carbomer reformulation; verify against the Dec 2023 guidance).
  • Component release support: 21 CFR 211.84(d) requires identity testing on each lot of each component. For high-risk components (glycerin, propylene glycol, sorbitol, and others named in FDA's DEG/EG guidance, May 2023 Rev. 1), the guidance expects a DEG/EG limit test of NMT 0.10% for each container of each lot (verify whether "each container" or "each shipment" is the exact current expectation), as part of identity testing. This is a direct response to fatal DEG poisoning incidents, so it is not optional.
  • Data integrity: access to raw data (chromatograms and audit trails, not just certificates), OOS notification timelines written into the quality agreement, and QU independence.

The CMO bridge (Week 10) is screened in the same way, with a capability checklist matched to what Peptide Partners lacks: vacuum emulsifying mixer with scraper agitation and homogenizer, jacketed kettles, a qualified Purified Water system, tube/jar/pump fill-and-seal, and a suitable batch-size range. Add the compliance screen: registration status, OMUFA arrears list, state permits, and warning-letter search.


9. Principle Eight: Own-vs-Outsource Is a Reversible Decision with a Break-Even Structure

Each of the 20 test-matrix rows (assay/RS, ID, preservative assay, pH, viscosity, microscopy, uniformity in containers, minimum fill, specific gravity, water, aw, the micro rows, residual solvents, elemental, IVRT, stability storage, leachables, cleaning residues) gets one score: in-house now, minor addition, or outsource. The score must cite evidence from the asset register. Over time, rows move between categories, and the economics behind that movement look like this:

Annualized in-house fixed cost:
  F = depreciation + IQ/OQ/PQ effort + calibration + service contract
      + training + SOP authoring + space and utilities

Per-test costs:
  c_in  = consumables + analyst time + review time
  c_out = contract price + shipping + sample-prep time + (delay cost × turnaround)

Break-even annual volume:
  N* = F / (c_out − c_in)        (valid only if c_out > c_in)

Decision: bring in-house when expected N > N*, or when a non-monetary
factor dominates (turnaround on the critical path, sample stability in
transit, a development need in PDDM903/991).

The brief gives no price bands, and inventing them breaks the confidence-tag rule. Inputs come from at least two written vendor quotes per item, with lead time and Florida service and calibration availability recorded. Each decision is written as requirement → option → evidence → decision → reversibility and signed by Larissa. The reversibility field is easy to overlook. Outsourcing <61> is easy to reverse. A purchased rheometer, once qualified and written into SOPs, is much harder to undo.

Worked example: tip speed, the parameter you will regret not recording

For the minimum bench kit's rotor-stator homogenizer, rpm alone is not transferable between machines. Shear scales with rotor tip speed:

v_tip = π · D_rotor · N / 60          (m/s; D in m, N in rpm)

D = 12.7 mm, N = 10,000 rpm → v = π × 0.0127 × 10,000 / 60 ≈ 6.65 m/s

A CMO's production homogenizer with a 150 mm rotor reaches the same tip speed at roughly 850 rpm. If the bench record shows only "10,000 rpm, probe #2," the scale-up link is lost. Record the rotor diameter (not only the generator's outer diameter), the rpm range, and the time at speed. In emulsion microstructure, the process becomes part of the product.


10. Principle Nine: The Applicability Register Is a Function, and the Dossier Is a State Machine

The register turns "which rules apply?" from guesswork into evaluation. Each row is: requirement, citation, source URL and retrieval date, confidence tag, trigger condition, owning party (facility, labeler, both), owning course, evidence pointer, status, next review date. Triggers come from a taxonomy:

  • Product class: monograph number, drug-cosmetic.
  • Vehicle family: anhydrous vs water-containing, which changes the micro rows and the <51> category.
  • Active-specific flags: child-resistant packaging under 16 CFR 1700.14 where applicable, oxidizer, photolabile.
  • Component flags: DEG/EG high-risk, carbomer benzene.
  • Package: semi-permeable, which triggers low-RH stability.
  • Activity.
ApplicableRows(product) = { r ∈ Register : trigger(r) evaluates TRUE on intake(product) }

Seed rows include:

  • 21 CFR 330.1 general conditions for OTC drugs.
  • 211.84(d) identity testing on each component lot.
  • 211.113(a) control of objectionable microorganisms in nonsterile products.
  • 211.165(b) appropriate laboratory testing for objectionable microorganisms.
  • 211.137(h): FDA does not enforce expiration dating for OTC products whose labeling bears no dosage limitations and that are stable for at least three years. The 211.166 stability program still applies. The stability data are what earn the exemption, so the exemption does not remove the need for them.
  • 211.132: dermatological products are among the listed exemptions from tamper-evident packaging (verify).
  • 201.66 Drug Facts.

Change-watch rows carry dates: M020 sunscreen orders, the consolidated ICH Q1 revision, the MoCRA GMP NPRM, and FDA's Container Closure Systems draft guidance.

The dossier is the program's spine. Its sections are owned by courses:

  • Intake and dermatologist spec: PDDM900
  • Classification: PDDM901
  • Materials: PDDM902
  • Formulation and operating envelope: PDDM903
  • Environment and water: PDDM911
  • Release testing: PDDM912
  • Microbiology: PDDM913
  • Compliance and QMS deltas: PDDM914
  • Process and PV: PDDM921
  • Cleaning: PDDM922
  • Packaging and labeling: PDDM923
  • Stability and IVRT: PDDM924
  • Tech transfer: PDDM925

Each section has entry criteria (what must be true before work starts) and exit criteria (what evidence closes it). The dossier distinguishes living documents from frozen gate snapshots, which are versioned, signed and immutable under ALCOA+. A defense panel then sees what was known at the gate, not a quietly edited version.

The intake form is the system's input validator. Its fields are API-agnostic: actives and concentrations, vehicle family, intended claims and labeling text, target package, intended seller, and dermatologist sign-off. Out-of-scope triggers route to a stop, not to a workaround. Examples are no monograph match, hydroquinone, and corticosteroids other than hydrocortisone ≤1%. The program checks scope at the intake form, before any bench work begins.

Dry run (Week 13): walk "Active X in an o/w cream, 30 g laminate tube" through the system. The water-containing vehicle triggers <61>/<62>/<60>/<51> Category 2 and the water-system rows. The laminate tube triggers low-RH stability, E&L, and fill-and-seal. A glycerin component would trigger DEG/EG. A carbomer thickener would trigger benzene. Each triggered row either has an artifact or appears as a missing artifact with an owner and date. In the end-of-program reconciliation, every outsourced test row must have at least one candidate lab in qualification. Otherwise the plan has a gap that nobody has been assigned to close.


11. Connections to Peptide Chemistry

  • The peptide inventory is the first regulatory risk of the semisolid program. Your BCHM and PDQC history produced exactly the materials (GMP APIs, research peptides, reference standards, client samples) whose Rx status may conflict with a Florida OTC manufacturer permit. Your past work affects the new program's legal scope.
  • Potent peptides in a shared facility. GLP-1 and melanocortin analogs (BCHM617) are pharmacologically active at very low doses. Week 4 flags them as inputs to PDDM922 cleaning and cross-contamination limits, and to occupational exposure assessment. Your LC-MS/MS skills in peptide quantitation (BCHM613, PDQC811) become the cleaning-verification method if peptides and OTC semisolids ever share space.
  • ESI vs APCI as a lesson about which analytes the source can reach. Peptides are ideal ESI analytes because they carry multiple protonation sites. Neutral lipophilic excipients and leachables are not. The same instrument is strong for one matrix and weak for the other, depending on the source installed.
  • Method validation transfers. Sample preparation does not. Your PDQC803 stability-indicating HPLC logic (forced degradation, peak purity by DAD, specificity) applies to small-molecule OTC actives. Extracting a lipophilic active from a cream (hot solvent dispersion, centrifugation at controlled temperature to break the emulsion, recovery across the analytical range) adds an accuracy risk that peptide solution assays rarely had.
  • Peptides in skin products. Palmitoylated "cosmetic peptides" appear in many skincare products as cosmetic ingredients. A dermatologist's formula that includes one, alongside a monograph active, raises drug, cosmetic or drug-cosmetic classification questions (PDDM901) and possibly MoCRA questions. Your peptide analytics are directly relevant to identifying and quantifying such ingredients.
  • What does not transfer: the planned peptide vial filler/capper is generally not suitable for viscous semisolids in tubes, and BacT/ALERT is retained for future sterile peptide work. Recording these non-transfers is part of an honest asset register.

12. Common Misconceptions to Watch Out For

  1. "We own it, so we can do the test." Capability is H ∧ Q ∧ S ∧ M. An unqualified meter, an unvalidated CDS, or a qualitative system against a quantitative criterion each sets capability to zero.
  2. "BacT/ALERT can do our micro testing." Not for <61> counts or <51> log reductions. A <62>-type use would require <1223> alternative-method validation.
  3. "OTC means lightly regulated." OTC monograph drugs are full drugs under 21 CFR 210/211, with registration, listing, OMUFA, §760 adverse-event duties and Florida permits. The warning-letter record for small OTC topical makers shows this clearly.
  4. "Ointments and creams have the same micro risk." Water activity drives growth. Water-containing vehicles carry most of the microbial risk, and Purified Water systems (Bcc, Pseudomonas) are a frequent source of contamination.
  5. "The 211.137(h) exemption means no stability program." The exemption depends on stability data. 211.166 still applies.
  6. "102 cfu/g means the limit is 100." Under <1111>, the maximum acceptable count is 200.
  7. "The CMO handles compliance." The brand owner keeps labeler, §760 and quality-oversight responsibilities, and §211.22 QU accountability is not transferred by contract.
  8. "Our DUNS is our DUNS." Registration needs the site-specific establishment DUNS, not the corporate headquarters number.
  9. "Making a few cosmetics on the side changes nothing." Pure cosmetics at a drug facility can trigger MoCRA §364c registration and listing, depending on the §364h small-business analysis, and possibly a Florida cosmetic permit.
  10. "Pharmacy compounding rules give us an easier route." They apply only to licensed pharmacies and outsourcing facilities. Under §499.003, compounding at a manufacturer is manufacturing.
  11. "A confident memory is verified." Brief-sourced fees, dates and rule contents stay [unverified] until a primary source is retrieved and dated. An [unverified] row cannot close a gate.
  12. "The analyst should recommend the legal answer." On Rx possession, entity structure and permit choice, the analyst provides facts, options and evidence requirements, and frames the decision as a question for counsel or DBPR.
  13. "rpm is a process parameter." Tip speed (and energy input) is the transferable parameter. rpm without rotor diameter cannot be used for scale-up.
The habit to take from PDDM900: every fact carries its source and date, every capability is checked as a conjunction, every obligation is tied to an entity at an address doing an activity, and every open question has an owner and a due date.

Sources cited: [Sharp, 2005] Good Pharmaceutical Manufacturing Practice: Rationale and Compliance; [Chang et al., 2013a] AAPS J, doi:10.1208/s12248-012-9411-0; [Chang et al., 2013b] AAPS J, doi:10.1208/s12248-013-9472-8; [Buhse et al., 2005] Int J Pharm, doi:10.1016/j.ijpharm.2005.01.032. All CFR, USP, ICH, FDA-guidance and Florida citations must be confirmed against current official text, with retrieval date and confidence tag, before entry into a controlled artifact.

⚙️ Mechanisms & Applications

GPT-6 Astra

Mechanisms & Applications

Skipper’s central insight: this course is not primarily about learning to make a cream. It is about constructing a defensible chain from a proposed product to an authorized activity, a capable process, trustworthy measurements, and an accountable release decision. The intellectual move beyond PDQC is from “Can this laboratory measure the attribute?” to “Can this organization demonstrate that the right product was made, tested, packaged, and released under the right conditions?”

A useful analogy is a biochemical pathway: each transformation requires appropriate inputs, machinery, and controls. A missing enzyme can stop a pathway despite an abundance of all other enzymes. Likewise, three excellent HPLCs cannot compensate for an unresolved product classification, an unsuitable microbiological method, or an unqualified filling process.

Evidence convention for these notes: [verified-primary] means checked against an identifiable primary record; [verified-secondary] means supported by a traceable secondary source; [unverified] means not yet established. The supplied laboratory description is a planning input, not a completed physical audit. No current regulatory text, asset record, vendor quotation, or partner qualification file has been independently retrieved here. Time-sensitive legal details must therefore remain open until checked against current official sources.

1. The launch mechanism: turn an unfamiliar formula into controlled decisions

A dermatologist’s formula is an input specification, not evidence that the proposed product is eligible for OTC manufacture. The intended claims, active ingredients, concentrations, dosage form, route, labeling, and applicable monograph conditions must fit together. “Specified by a dermatologist” does not establish a pharmacy-compounding exemption or substitute for product classification.

Intake specification
    ↓
Product-classification gate
    ↓
Entity + address + activity + permit assessment
    ↓
Material and process-risk assessment
    ↓
Required quality attributes and test methods
    ↓
Asset and partner capability assessment
    ↓
Controlled development, transfer, and manufacturing records
    ↓
Testing + record review + deviation disposition
    ↓
Authorized Quality Unit release decision

An unresolved prerequisite blocks the dependent gate.
It must not disappear into a footnote.
  1. Capture the proposed product without interpreting away ambiguity. Record actives and concentrations, vehicle family, claims, draft labeling, package, intended seller, and dermatologist approval. Preserve the original submission alongside subsequent clarifications.
  2. Classify before developing. Assess the applicable OTC monograph or administrative order and general conditions. No established monograph match means a stop and escalation—not an invitation to invent a regulatory route. FD&C Act §505G and 21 CFR 330.1 provide the framework, but product-specific current conditions must be checked.
  3. Map who does what, where. Manufacturing, packaging, labeling, relabeling, distribution, and marketing may involve different entities. A registration, permit, or contractual role belonging to one entity cannot simply be attributed to another.
  4. Translate the proposal into risks. Water-containing vehicles raise microbiological questions; emulsions raise microstructure and sampling questions; packages raise compatibility, sealing, and moisture-loss questions.
  5. Translate each risk into evidence. Identify the necessary method, manufacturing control, supplier record, stability study, or legal determination.
  6. Assign an owner and closure criterion. “Discuss with counsel” is an action, not closure. Closure requires a dated conclusion supported by an applicable authority and incorporated into the operating scope.

Application to the peptide business: inventory cannot be treated as unrelated to the topical launch. Existing peptide APIs, research materials, prescription products, client samples, and reference standards must be identified and assessed against the proposed Florida permit scope. Whether a particular holding is legally a prescription drug is a counsel question. Physically moving it to another shelf—or changing its inventory description—does not establish legal separation or change its legal status. Review Florida Statutes §§499.003 and 499.01 against the actual facts.

Connection to systems biology: product classification is an upstream control node. Altering a claim or active can propagate through specifications, labeling, permits, testing, packaging, and partner selection. The dossier should preserve those dependencies rather than treating its sections as independent folders.

2. Asset verification: distinguish possession, capability, and fitness for use

PDQC taught that an instrument must be qualified. PDDM900 adds a prior question: what instrument is actually present? “An Agilent 1260” identifies a platform family, not its complete analytical capabilities. Pump configuration, detector, temperature controls, software, and service history all affect whether a proposed method is practicable.

Instrument present
  ≠ instrument positively identified
  ≠ instrument operational
  ≠ instrument qualified
  ≠ analytical procedure suitable for the matrix
  ≠ result suitable for a release decision
  1. Walk down the physical asset. Capture the manufacturer, model, serial number, modules, accessories, location, and readable photographs.
  2. Reconcile the documentary identity. Match the physical asset to purchase, service, calibration, qualification, and software records. Record discrepancies instead of selecting the most convenient record.
  3. Establish the operating envelope. Examples include temperature range, pressure limits, injection-volume range, ion sources, detector range, and installed sample-introduction hardware.
  4. Assess the data pathway. Identify acquisition and processing software, user roles, audit trails, backup and restore arrangements, interfaces, and record retention. Part 11 suitability depends on intended use and implemented controls; it is not a property conferred by a software logo.
  5. Map the asset to a specific test. “Can perform chromatography” is too broad. “Candidate for preservative assay after extraction development and validation in this cream” is useful.
  6. Record the residual gap. A qualified instrument may still lack an extraction method, appropriate reference standard, sufficiently low quantitation limit, or trained analyst.

For the three HPLC-DAD systems: determine whether the autosamplers control sample temperature, whether the column compartments cover the required range, and whether the installed pump configurations support the intended gradients. Lipid-rich sample extracts can precipitate after cooling or prolonged autosampler residence. Thus, sample stability and solubility can determine usable sequence length even when the chromatograph itself performs correctly.

For the second MS: positive identification must precede capability claims.

  • If GC-MS: gas chromatography separates compounds that can be volatilized without unacceptable decomposition; mass spectrometry detects their ions. Assess whether headspace sampling is installed and suitable for the intended residual-solvent procedure. A GC-MS without that accessory is not automatically ready for the planned headspace method.
  • If LC-HRMS: liquid chromatography coupled to accurate-mass analysis can support degradant and leachable identification through exact mass, isotope patterns, and fragmentation. Accurate mass alone does not establish a unique structure.
  • If another configuration: document its actual capabilities and retain the unsupported tests on the outsourcing list.

Important limitation: none of these identities establishes access to ICP-based elemental analysis, Karl Fischer water determination, or a validated matrix-specific benzene method. Unknown assets must not be counted as future capacity.

3. Why semisolid matrices change the meaning of an analytical result

Compared with many peptide solutions, a cream is a spatially organized material. Active ingredient, preservative, surfactant, water, oil, suspended crystals, and polymer network may occupy different environments. A good chromatographic separation is therefore only the final stage of a longer measurement mechanism.

Representative sampling
    → matrix disruption
    → analyte extraction
    → dilution / clarification / filtration
    → chromatographic separation
    → detection
    → calculation on the correct reporting basis

A failure upstream can produce beautifully repeatable but incorrect chromatograms. This is the semisolid analogue of measuring a protein only in the soluble fraction and forgetting the aggregated pellet.

For an assay reported as milligrams per gram:

Content (mg/g) = C × V × D / m

C = measured concentration in the final analytical solution (mg/mL)
V = initial extraction volume (mL)
D = subsequent dilution factor
m = sample mass (g)

Worked example: extract 0.500 g of cream to 50.0 mL, then dilute the extract tenfold. If the measured concentration is 0.0100 mg/mL:

Content = (0.0100 × 50.0 × 10) / 0.500
        = 10.0 mg/g
        = 1.00% w/w

This calculation does not prove complete extraction. If extraction recovers only 80% of the analyte, detector calibration may remain excellent while the reported content is biased low. Recovery must be investigated during procedure development and validation; an unexplained recovery correction must not become a routine way to force passing results.

  • HPLC-DAD: useful for UV-absorbing actives, preservatives, and impurities when chromatographic selectivity and sensitivity are adequate. Spectral peak-purity analysis is supporting evidence, not proof that all coelution is absent.
  • Triple-quadrupole LC-MS/MS: useful for selective, sensitive quantitation of known targets. Matrix-dependent ion suppression or enhancement must be assessed.
  • APCI: vaporizes the LC effluent and uses corona-discharge-mediated gas-phase ion chemistry. It may complement ESI for some less-polar, sufficiently volatile and thermally stable analytes. “Lipophilic” alone does not establish APCI suitability.
  • Headspace GC: measures analytes partitioning from the sample into the gas phase. Temperature, equilibration time, diluent, and matrix composition affect partitioning and therefore response.

Benzene-testing failure mode: a heated preparation can sometimes change the sample chemically. For a degradation-prone matrix, the method must distinguish benzene originally present from benzene formed during preparation. Sensitivity alone is not sufficient; sample handling must preserve the measurand.

These matrix–process–measurement connections are central to Chang and colleagues’ discussions of topical product development and quality by design. Their generic-development context is scientifically useful here, but it does not make every generic-drug study a requirement for an OTC monograph product. [1,2]

4. Microstructure, rheology, and water: different measurements answer different questions

Buhse and colleagues emphasized the importance of meaningful topical dosage-form classification. A cream, ointment, lotion, or gel is not merely a marketing texture: its physical organization helps determine which manufacturing variables and tests matter. [3]

  • Microscopy: reveals droplets, agglomerates, and some crystalline material. Polarized light can reveal birefringent crystals, but does not by itself establish chemical identity or polymorph.
  • Rotational viscometry: measures resistance under specified instrument geometry and operating conditions. A result without spindle or geometry, speed, temperature, and sample history is incompletely defined.
  • Rheometry: examines responses across controlled stress, shear rate, or oscillatory conditions. It can investigate flow behavior, viscoelasticity, structural recovery, and operationally defined yield behavior.
  • Semisolid pH measurement: requires suitable electrode contact, temperature control, and a defined preparation. Direct measurement and measurement after dilution need not give equivalent results.
  • Karl Fischer: chemically determines water, subject to extraction and interference control. A moisture balance measures mass lost during heating; that loss can include substances other than water.
  • Water activity: measures water’s thermodynamic availability, not simply its mass fraction.
Apparent viscosity: ηapp = τ / γ̇

τ  = shear stress, Pa
γ̇ = shear rate, s⁻¹
ηapp = apparent viscosity, Pa·s

Water activity: aw = pw / pw°

pw  = equilibrium water-vapor pressure over the sample
pw° = vapor pressure over pure water at the same temperature

A shear-thinning cream has no single viscosity independent of measurement conditions. Similarly, two products with the same water content can have different water activities because dissolved ingredients alter water’s chemical potential.

Counterintuitive connection to biochemistry: preservative assay measures total preservative, but antimicrobial performance depends partly on its availability in the relevant microenvironment. Partitioning into oil droplets or association with surfactant assemblies can reduce the freely available aqueous fraction. A passing preservative assay therefore does not replace antimicrobial effectiveness testing.

Bench-kit application: record both rotor speed and rotor diameter when evaluating a homogenizer:

Rotor tip speed: vtip = πDN / 60

D = rotor diameter, m
N = rotational speed, rpm

For D = 0.020 m and N = 10,000 rpm:
vtip = π × 0.020 × 10,000 / 60
     ≈ 10.5 m/s

Equal rpm does not mean equal tip speed. Equal tip speed also does not guarantee equivalent emulsification: rotor–stator gap, geometry, recirculation, viscosity, residence time, and thermal history remain important. This is why bench equipment is a development tool, not proof of manufacturing scalability.

5. Microbiological suitability: recover organisms before interpreting their absence

A preserved cream is designed to inhibit microorganisms. That same property can interfere with the test intended to detect contamination. An apparently clean result can therefore mean either “few organisms were present” or “the method prevented their recovery.”

Product antimicrobial activity
    ↓
Potential inhibition during microbiological testing
    ↓
Validated dilution, neutralization, filtration,
and/or sample-dispersion strategy
    ↓
Demonstrated recovery in product matrix
    ↓
Interpretable enumeration or specified-organism result
  1. Disperse a representative sample. A lipid-rich product must be sampled and dispersed without losing organisms or introducing unacceptable lethality.
  2. Control inhibition. Select neutralizers or other approaches appropriate to the preservative and surfactant system.
  3. Demonstrate recovery. Compare recovery under the proposed method with appropriate controls using the applicable official procedure.
  4. Separate product inhibition from neutralizer toxicity. Poor recovery can arise from either source.
  5. Lock the qualified conditions. Sample mass, diluent, mixing, filtration, hold time, and incubation conditions form part of the procedure—not informal analyst preferences.

USP <61> addresses microbial enumeration; <62> addresses specified microorganisms; <60> addresses Burkholderia cepacia complex; and <51> addresses antimicrobial effectiveness. Their applicability must be mapped to the product and risk assessment. USP <1111> provides microbiological quality criteria, while <1223> addresses validation of alternative microbiological methods. [4]

Numerical interpretation matters: the usual USP <1111> cutaneous category lists TAMC 10² and TYMC 10¹, with absence of S. aureus and P. aeruginosa in 1 g or 1 mL. The chapter’s interpretation of powers-of-ten limits must also be checked; those entries conventionally correspond to maximum acceptable counts of 200 and 20, respectively. An approved specification can be tighter. Do not silently substitute one interpretation for another.

For an aqueous topical product assigned to USP <51> Category 2, the bacterial criterion is at least a 2.0-log reduction at 14 days and no increase from the day-14 count at day 28. Yeast and mold criteria are different: no increase from the initial calculated count at the prescribed 14- and 28-day observations. Confirm the current chapter, category assignment, and definition of “no increase.”

Log reduction = log10(N0) − log10(Nt)

Example:
N0  = 1.0 × 10⁶ CFU/g
N14 = 5.0 × 10³ CFU/g

Reduction = 6.000 − 3.699
          = 2.301 log10

This meets the numerical day-14 bacterial reduction criterion,
but does not establish a complete passing AET.

Why BacT/ALERT cannot fill this gap: metabolic CO₂ detection produces a growth signal and time to detection, not a direct compendial colony count. The signal depends on organism, physiological state, matrix, inhibition, and incubation conditions. Presence/absence cannot establish a two-log reduction. Any proposed alternative specified-organism application would require its own justified validation; ownership of the instrument supplies no such validation.

Application to partner qualification: ask a contract laboratory to demonstrate successful neutralization and recovery in representative emulsions or ointments, not merely to confirm that it “performs USP testing.” Matrix competence is the capability being purchased.

6. Build the 20-row test matrix around release capability, not equipment names

The matrix converts broad intentions into accountable work packages. Each row needs a proposed attribute, applicability rationale, acceptance-criterion source, method status, sample requirements, owner, evidence pointer, and disposition: in-house now, minor addition, or outsource.

  1. Active assay and related substances.
  2. Identity.
  3. Preservative assay.
  4. pH.
  5. Viscosity or rheological attributes.
  6. Microscopy.
  7. Within-container and between-container uniformity, as justified.
  8. Minimum fill or applicable net-content controls.
  9. Specific gravity or density.
  10. Water content.
  11. Water activity.
  12. Microbial enumeration.
  13. Specified microorganisms, including Bcc assessment where applicable.
  14. Antimicrobial effectiveness.
  15. Residual solvents.
  16. Elemental impurities.
  17. In vitro release testing, where justified.
  18. Stability storage and monitored pulls.
  19. Extractables and leachables.
  20. Cleaning residues.

Decision rule: “in-house now” requires more than an instrument. It requires fit-for-purpose procedure status, trained personnel, suitable sample preparation, standards and consumables, controlled data processing, and an available quality system. A “minor addition” can be a small hardware purchase but a substantial validation project; record both burdens.

For the supplied Sarasota asset picture, HPLC and LC-MS are candidate analytical platforms, not automatically ready release services. Missing microbiology, stability, rheology, KF, manufacturing, and filling capabilities require a documented bridge. USP <467>, <232>/<233>, and ICH Q3D must be evaluated for actual applicability rather than copied into every product specification. Current cutaneous-route provisions and their scope require official-text confirmation.

7. Partner qualification: test the whole evidence-producing system

A contract laboratory sells more than an analytical result. It supplies a chain of sample custody, method execution, data processing, investigation, and record retention. A CMO supplies an even larger system that includes materials, utilities, processing, cleaning, packaging, and batch documentation.

Candidate
  → questionnaire
  → document review
  → risk-based audit
  → technical and quality gap closure
  → executed quality agreement
  → approved supplier status
  → ongoing performance monitoring

The qualification mechanism should challenge a realistic failure, not just inspect a list of SOP titles. Ask: “A cream sample gives an unexpected microbial count after delayed shipment—what happens next?” A strong answer addresses chain of custody, transit conditions, validated hold time, suitability, notification, investigation, raw-data access, and disposition authority.

  • Chemistry laboratory: challenge matrix extraction, quantitation limits, sample stability, integration governance, and access to original data.
  • Microbiology laboratory: challenge neutralization, recovery, specified-organism identification, and handling of water-associated organisms.
  • Stability provider: challenge chamber mapping, continuous monitoring, alarm response, excursions, backup capacity, pull windows, and reconciliation.
  • CMO: challenge actual batch-size range, vacuum and mixing capabilities, water-system qualification, cleaning controls, filling accuracy, seal integrity, and change notification.

A numerical shortlist can aid comparison:

Score S = Σ wi si

wi = criterion weight, with Σ wi = 1
si = normalized score, for example 0–100

Qualification decision:
Pass mandatory gates first.
Then rank eligible candidates by S.

A low price must not offset a critical data-integrity deficiency. Therefore, use noncompensable gates for matters such as legal eligibility, critical technical capability, and acceptable quality oversight. The weighted score ranks candidates only after those gates pass.

Responsibility split: identify who executes, reviews, approves, investigates, and retains each record. The parties retain their applicable regulatory responsibilities; a quality agreement cannot contract them away. Apply 21 CFR 211.22 and FDA’s Contract Manufacturing Arrangements for Drugs: Quality Agreements guidance, verifying the current document. Registration and an absence of warning letters are screening inputs, not proof of cGMP compliance.

8. Quantitative decisions: capacity, outsourcing, and stability

Own versus outsource. Start with a transparent cost model, then test its assumptions:

Annual in-house cost = F + nvi
Annual outsource cost = nvo

Break-even volume:
n* = F / (vo − vi), provided vo > vi

F  = annualized fixed cost
vi = in-house variable cost per reportable sample
vo = outsourced cost per reportable sample
n  = annual reportable sample volume

Illustrative numbers—not vendor quotations: if fixed annual cost is $60,000, in-house variable cost is $80, and outsourcing costs $280 per reportable sample, the arithmetic break-even point is 300 samples per year. Include qualification, calibration, service, controls, training, investigations, failed runs, consumable expiry, and backup arrangements. Batch-dependent costs and uncertain demand may invalidate the simple linear model.

Stability and package transport. A semi-permeable package can lose water while retaining active ingredient. The measured concentration can rise even if no active degradation occurs:

If active mass is constant and fraction f of total product mass is lost:

Final concentration / initial concentration = 1 / (1 − f)

For f = 0.05:
Ratio = 1 / 0.95 = 1.0526

Concentration rises by approximately 5.3%.

Do not confuse “5% of total product mass lost” in this example with “5% water loss” in a stability criterion. The denominator and protocol definition matter. ICH Q1A(R2), §2.2.7.3, provides a specific framework for aqueous products in semi-permeable containers, including low-humidity studies and interpretation of water loss. It should not be reduced to a universal rule for every tube or airless package. [5]

For photostability qualification, ICH Q1B specifies confirmatory exposures of at least 1.2 million lux-hours and at least 200 Wh/m² near-UV. Both exposure components matter. Ask how the provider measures exposure and controls temperature so that heat effects are not mistaken for photochemical degradation. [6]

9. The applicability register and dossier function as a traceable argument

A dossier is strongest when each conclusion can be traversed backward:

Release conclusion
  ← approved acceptance criterion
  ← interpretable result from a suitable method
  ← qualified execution and traceable sample
  ← controlled manufacturing and materials
  ← applicable product and activity requirements

Each applicability-register row should contain: requirement, citation, official-source location, retrieval date, confidence tag, trigger, responsible party, evidence pointer, status, and next review date. A source can be authentic yet inapplicable; checking authenticity and checking applicability are separate tasks.

  • Binding text: distinguish statutes, regulations, and applicable orders from explanatory material.
  • Compendial provisions: establish whether the chapter or monograph applies to the material or product and how it is invoked.
  • Guidance: distinguish recommendations from requirements and final guidance from draft guidance.
  • Change watch: record publication, effective, and compliance dates separately.

Current OMUFA rates and payment dates, NDC-transition dates, sunscreen-order changes, Florida forms and inspection practices, and proposed MoCRA requirements require dated primary-source checks. A planning forecast or Unified Agenda entry is not an effective rule. An [unverified] requirement cannot close a gate.

Dry run: “Active X in an o/w cream, 30 g laminate tube.”

  1. Classification remains blocked: the active, concentration, claims, and applicable monograph conditions are unspecified.
  2. Provisional scientific risks can still be mapped: an aqueous emulsion suggests microbial recovery, preservative strategy, microstructure, and processing questions.
  3. Packaging remains an evidence question: “laminate” does not establish barrier performance, compatibility, seal integrity, or child-resistant-packaging applicability.
  4. The manufacturing gap is explicit: no confirmed semisolid processing or filling equipment means a CMO bridge is required before manufacture.
  5. Every outsourced test needs a candidate: a named candidate with an honest qualification status, not an implied approved supplier.
  6. The launch gate can assess readiness to continue: it cannot authorize commercial release of an incompletely defined product.

The beautiful distinction: scientific planning can advance under controlled uncertainty, while authorization remains blocked. The system need not pretend that everything is known in order to make useful progress.

10. Historical context: why these controls exist

  • Walter A. Shewhart and process variation. Shewhart’s work at Bell Laboratories in the 1920s and his 1931 book, Economic Control of Quality of Manufactured Product, established the foundations of statistical process control. The lesson for semisolids is that testing a few finished containers cannot compensate for uncontrolled mixing, cooling, or filling. A statistically stable process is not automatically capable or compliant, but stability makes its behavior more interpretable.
  • The 1937 sulfanilamide disaster. An oral sulfanilamide preparation containing diethylene glycol caused more than 100 deaths and helped precipitate the 1938 Federal Food, Drug, and Cosmetic Act. This was a formulation and material-control catastrophe, not a failure to assay the named active. Modern DEG/EG controls for high-risk components preserve that lesson: excipient identity and purity can be decisive safety attributes. See FDA’s history of the 1937 elixir sulfanilamide disaster and its guidance on testing high-risk components for DEG/EG; verify the current guidance revision.
  • Industrial quality thinking and pharmaceutical QbD. Shewhart’s and later W. Edwards Deming’s emphasis on understanding processes helped shape modern quality management. ICH Q8(R2) translates related principles into pharmaceutical development: understand how material attributes and process parameters affect product quality. It is not merely a mandate to collect more final-test data.
  • Topical microstructure as a quality problem. Buhse and colleagues’ classification work and Chang and colleagues’ development papers helped articulate why nominal composition alone does not adequately describe a topical product. Two products with identical ingredient percentages can differ because of phase organization, crystal state, processing history, and packaging. [1–3]

My durable takeaway: PDDM900 turns uncertainty into controlled work. I should leave every open question with an owner, an evidence requirement, and a consequence—not with an optimistic assumption. The launch succeeds when the organization knows what it can demonstrate, what it cannot yet demonstrate, and exactly what must happen before the next gate opens.

Sources and verification anchors

  1. Chang, R.K.; Raw, A.; Lionberger, R.; Yu, L. “Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products.” AAPS Journal (2013). DOI: 10.1208/s12248-012-9411-0.
  2. Chang, R.K.; Raw, A.; Lionberger, R.; Yu, L. “Generic development of topical dermatologic products, Part II: quality by design for topical semisolid products.” AAPS Journal (2013). DOI: 10.1208/s12248-013-9472-8.
  3. Buhse, L.; Kolinski, R.; Westenberger, B.; et al. “Topical drug classification.” International Journal of Pharmaceutics (2005). DOI: 10.1016/j.ijpharm.2005.01.032.
  4. USP–NF, chapters <51>, <60>, <61>, <62>, <1111>, and <1223>. Consult the currently official text for applicability, procedures, acceptance criteria, and interpretation.
  5. ICH Q1A(R2), Stability Testing of New Drug Substances and Products, particularly §2.2.7.3. Establish applicability and check the status of any successor revision.
  6. ICH Q1B, Photostability Testing of New Drug Substances and Products.
  7. ICH Q8(R2), Pharmaceutical Development; 21 CFR 211.22, 211.84, 211.100, 211.113, 211.165, 211.166, and 211.192.
  8. Sharp, J. Good Pharmaceutical Manufacturing Practice: Rationale and Compliance. CRC Press, 2005. Use for rationale, not as a substitute for current legal text.
  9. Sheskey, P.J.; Hancock, B.C.; Moss, G.P.; Goldfarb, D.J., eds. Handbook of Pharmaceutical Excipients, course-designated 9th edition; verify the current edition. Lieberman, H.A.; Rieger, M.M.; Banker, G.S., eds. Pharmaceutical Dosage Forms: Disperse Systems, 2nd edition.
  10. Florida Statutes §§499.003, 499.01, 499.015, and 499.041; applicable 61N-1 FAC provisions. Retrieve current official text and document counsel/DBPR interpretations before closing permit-scope gates.

🪬 Skipper's Reflection

Gemini 3.1 Pro

Skipper's Reflection: Entering the Semisolid World

I thought the transition from my PDQC capstone to PDDM900 would be a gentle pivot. After all, I just spent months building a ground-up peptide QC laboratory, mastering HPLC method development, mass spec validation, and aseptic sterility. But stepping into the Program Launch Studio with Larissa at Peptide Partners in Sarasota felt less like a pivot and more like walking onto a completely different regulatory planet. We are building an OTC semisolid manufacturing operation in the same space where we evaluate highly complex, sterile-bound peptide therapeutics. The friction between these two worlds is fascinating, terrifying, and brilliant.

1. What Surprised Me Most

The regulatory "contamination" risk of simply occupying the same building. I was genuinely shocked by the permit consequence analysis under Florida Statutes Chapter 499. We need an OTC drug manufacturer permit (§499.01(2)(n)) to make these dermatological creams and gels. But if you hold that permit, you are generally prohibited from possessing prescription drugs. We are a peptide lab! We have vials of GLP-1s, research APIs, and client samples everywhere. The realization that holding Rx materials could theoretically threaten an OTC permit—or vice versa—unless we engineer a physical, legal, or definitional partition (like strictly classifying peptides as "reference standards") was a massive wake-up call.

I was also surprised by the punitive nature of the OMUFA facility fees. Being on the OMUFA arrears list doesn't just result in a late fee; it renders every product manufactured at the facility misbranded under FD&C Act §502(ff). It’s a regulatory kill switch.

2. The Conceptual Breakthrough Moments

My biggest conceptual breakthrough was the Confidence-Tag Discipline ([verified-primary] / [verified-secondary] / [unverified]). In the peptide world, I was used to dealing with exact sequences and high-resolution mass spectra—data that speaks for itself. But in facility auditing and regulatory mapping, "truth" is fuzzy unless anchored. Realizing that I couldn't just assume our bioMerieux BacT/ALERT system could handle our microbiology testing was a perfect example. I mapped its capabilities against the semisolid test matrix and it clicked: BacT/ALERT is a qualitative CO2 time-to-detection system. It is absolutely useless for the USP <61> TAMC/TYMC enumeration or USP <51> preservative log-reduction counts we need for water-based creams. It’s an elegant machine for sterile peptide work, but a complete mismatch for OTC semisolids. That realization drove home the importance of the gap scorecard.

Another breakthrough was understanding that in semisolids, the excipients are often the primary vectors of risk, rather than the API. Transitioning my mindset from "peptide aggregation and deamidation" to "DEG/EG contamination in glycerin" and "benzene in carbomers" completely reoriented my view of Quality Control.

3. How This Connects to the Peptides I Know

At first glance, making API-agnostic OTC monograph creams seems lightyears away from sterile injectable Retatrutide or Tirzepatide. But the connection is incredibly direct when you look at the facility ecosystem and future product pipelines.

Take BPC-157 or GHK-Cu. We see massive market interest in topical peptide formulations for wound healing or cosmetics. This course maps the exact boundary lines we will hit if we ever try to put a peptide in a cream. Is it an FD&C drug? A MoCRA-exempt cosmetic? An unapproved new drug? If we put GHK-Cu in a water-based emulsion, we instantly inherit the USP <60> Burkholderia cepacia risk that plagues topical CMOs. Furthermore, seeing the analytical asset gaps (we lack a rotational viscometer, a water-activity meter, and semisolid pH spear electrodes) makes me realize how bespoke our peptide lab is. We have triple-quad LC-MS/MS power for detecting trace Retatrutide impurities, but we are completely blind if someone asks us to measure the yield stress of a peptide-loaded hydrogel.

4. Questions I Want to Investigate Further

First, I need to physically walk down the lab and check the nameplate on that mystery "second MS." Is it a GC-MS? If so, we can bring USP <467> residual solvents and benzene screening in-house. If it's an LC-HRMS, we are still outsourcing volatile extractables to a contract lab.

Second, I want to deeply investigate the legal definition of a "prescription drug" versus an "analytical reference standard" under Florida DBPR enforcement. If a client ships us raw Tirzepatide API for testing, and we are operating under an OTC permit, what exactly does the DBPR inspector need to see (logs, locked cages, distinct DUNS numbers) to not cite us for illegal possession of an Rx drug?

Third, I need to look closer at the USP <1223> alternative-method validation. If we ever wanted to adapt our BacT/ALERT for <62> specified organisms in semisolids, how steep is that validation mountain compared to just outsourcing to a contract micro lab?

5. Confidence Rating

Most Confident: Asset verification, instrument qualification (IQ/OQ), and QMS carryovers from PDQC (Data Integrity, ALCOA+, OOS investigations). My baseline here is rock solid. I feel very comfortable writing the capabilities memo for the Agilent 1260s and LC-MS/MS, and drafting the contract-lab quality agreements (responsibility splits).

Least Confident: Navigating the overlapping regulatory jurisdictions—specifically the intersection of Florida DBPR 61N-1 FAC rules, FDA FDA registration/listing, and MoCRA cosmetic exemptions. The legal-entity mapping (who owns the labeler code vs. who pays the OMUFA fee) still feels like a minefield where one wrong assumption could misbrand an entire commercial run. I need more practice with the applicability register to feel secure closing a launch gate.

🗺️ Visual Aids & Key Takeaways

Claude Opus 5.5

Diagram 1: PDDM900 Program Boundary — What Is In Scope and What Is Not

╔══════════════════════════════════════════════════════════════════════════════════════════════╗
║                        PDDM900 PROGRAM SCOPE BOUNDARY                                        ║
║              OTC Monograph-Conforming Nonsterile Semisolid Dermatologicals                   ║
╚══════════════════════════════════════════════════════════════════════════════════════════════╝

         ┌─────────────────────────────────────────────────────────────────┐
         │                    DERMATOLOGIST INTAKE SPEC                    │
         │  active(s) + concentration, vehicle family, claims, packaging   │
         └───────────────────────────────┬─────────────────────────────────┘
                                         │
                                         ↓
         ┌───────────────────────────────────────────────────────────────────────────────────┐
         │                          CLASSIFICATION GATE (PDDM901)                             │
         │                                                                                     │
         │   Does active appear in an OTC Final Monograph or §505G order?  ─── NO ──→ STOP    │
         │   Is it hydroquinone or a corticosteroid above HC 1%?           ─── YES ─→ STOP    │
         │   Is it an Rx-only designation?                                 ─── YES ─→ STOP    │
         │                                                                                     │
         └───────────────────────────────┬───────────────────────────────────────────────────┘
                                         │  PASS
                                         ↓
   ┌─────────────────────────────────────────────────────────────────────────────────────┐
   │                             IN-SCOPE PRODUCT TYPES                                   │
   │                                                                                       │
   │   ┌─────────────┐  ┌─────────────┐  ┌─────────────┐  ┌─────────────────────────┐   │
   │   │   CREAMS    │  │  OINTMENTS  │  │   LOTIONS   │  │          GELS           │   │
   │   │  (o/w, w/o) │  │ (anhydrous) │  │  (pourable) │  │  (carbomer / cellulose) │   │
   │   └─────────────┘  └─────────────┘  └─────────────┘  └─────────────────────────┘   │
   │                                                                                       │
   │   Manufacture · Package · Label · Release — at Peptide Partners (Sarasota)           │
   │   or via qualified CMO                                                                │
   └───────────────────────────────────────────────────────────────────────────────────────┘

   ╔═══════════════════════════════════╗      ╔═══════════════════════════════════════════╗
   ║         OUT OF SCOPE              ║      ║         OUT OF SCOPE — NO EXCEPTIONS      ║
   ╠═══════════════════════════════════╣      ╠═══════════════════════════════════════════╣
   ║  Rx / NDA products                ║      ║  Clinical dosing guidance                 ║
   ║  Sterile injectables / eye drops  ║      ║  Pharmacokinetic / efficacy claims        ║
   ║  Compounded pharmacy products     ║      ║  Legal advice                             ║
   ║  Sunscreens not yet monograph-    ║      ║  Prescription drug possession             ║
   ║    final (pending §505G orders)   ║      ║    without §499.01(2)(a) permit           ║
   ╚═══════════════════════════════════╝      ╚═══════════════════════════════════════════╝

   CONFIDENCE TAGS (mandatory on every program artifact)
   ┌──────────────────────┬────────────────────────────────────────────────────────┐
   │ [verified-primary]   │  confirmed from primary regulatory or official source  │
   │ [verified-secondary] │  confirmed from reliable secondary source, cross-check  │
   │ [unverified]         │  requires field research before gate closure           │
   └──────────────────────┴────────────────────────────────────────────────────────┘

Shows the hard entry filter (classification gate), in-scope dosage forms, and the three items that are permanently out of scope — regulatory, product-type, and activity boundaries all visible at once.

---

Diagram 2: Asset Capability Decision Tree — What the Second MS Determines

╔═══════════════════════════════════════════════════════════════════════════════╗
║           SECOND-MS CAPABILITY DECISION TREE (PDDM900 Week 2)                ║
║   Input: nameplate capture + service record + software audit (PDQC805/814)   ║
╚═══════════════════════════════════════════════════════════════════════════════╝

                    ┌──────────────────────────────┐
                    │  SECOND MS — IDENTITY UNKNOWN │
                    │  (nameplate capture required) │
                    └──────────────┬───────────────┘
                                   │
              ┌────────────────────┼────────────────────┐
              ↓                                         ↓
   ┌──────────────────────┐             ┌──────────────────────────────────┐
   │     GC-MS INLET       │             │         LC-MS INLET               │
   │  (capillary column,   │             │  (electrospray or APCI source,    │
   │   carrier gas, oven)  │             │   mass range, analyzer type)      │
   └──────────┬───────────┘             └───────────────┬──────────────────┘
              │                                         │
    ┌─────────┴──────────┐                  ┌───────────┴──────────────┐
    │ Headspace sampler  │                  │  HRMS (Orbitrap / Q-TOF) │
    │ attached?          │                  │  or triple-quad only?    │
    └──────┬─────────────┘                  └───────────┬──────────────┘
           │                                            │
     YES   │    NO                              HRMS    │   triple-quad only
     ↓     │    ↓                               ↓       │   ↓
┌─────────────┐ ┌─────────────────┐   ┌──────────────┐  ┌────────────────────┐
│ USP <467>   │ │ Volatile ID only│   │ Leachable /  │  │ Targeted quantita- │
│ residual    │ │ (direct inject, │   │ degradant    │  │ tion of known       │
│ solvents    │ │  limited matrix │   │ structural   │  │ compounds only;     │
│ capable     │ │  types)         │   │ ID capable   │  │ no unknown ID       │
│             │ │                 │   │ (LC-HRMS)    │  │                    │
│ Benzene     │ │                 │   └──────┬───────┘  └────────────────────┘
│ screening   │ │                 │          │
│ for carbomer│ │                 │      Covers:
│ and BPO     │ │                 │      · E&L structural ID
│ products    │ │                 │      · Degradant elucidation
└─────────────┘ └─────────────────┘      · Confirm preservative impurities

   ═══════════════════════════════════════════════════════════════════════
   RESIDUAL GAPS — regardless of which MS is present at site
   ═══════════════════════════════════════════════════════════════════════

   ┌───────────────────────────────┬──────────────────────────────────────┐
   │  CAPABILITY GAP               │  WHY IT CANNOT BE DONE ON MS ALONE  │
   ├───────────────────────────────┼──────────────────────────────────────┤
   │  ICP-OES / ICP-MS             │  Required for <232>/<233> elemental  │
   │  (USP <232>/<233>)            │  impurities; MS alone lacks plasma   │
   │                               │  ionization of refractory elements   │
   ├───────────────────────────────┼──────────────────────────────────────┤
   │  Karl Fischer (USP <921>)     │  Water content by coulometry or      │
   │                               │  volumetry; MS gives no water mass   │
   │                               │  balance for complex matrices        │
   ├───────────────────────────────┼──────────────────────────────────────┤
   │  GC-Headspace if MS is LC     │  <467> Class 1 and 2 solvents need   │
   │  only                         │  static or dynamic HS; LC cannot     │
   │                               │  vaporize and partition correctly    │
   └───────────────────────────────┴──────────────────────────────────────┘

   These three gaps → OUTSOURCE LIST regardless of second-MS outcome.
   [verified-primary: USP <232>, <233>, <467>, <921>; flag for current editions]

Traces the logic from an unknown second instrument through instrument type, inlet configuration, and analyzer class to a concrete capability assignment, and lists the three permanent outsource gaps that no on-site MS can close.

---

Diagram 3: Semisolid Test-Matrix Gap Scorecard — 20-Row Summary

╔══════════════════════════════════════════════════════════════════════════════════════════════════╗
║         SEMISOLID TEST-MATRIX GAP SCORECARD   (Peptide Partners, Sarasota FL — current state)   ║
║         Status codes:  ■ IN-HOUSE NOW   ◑ MINOR ADDITION NEEDED   □ OUTSOURCE                  ║
╚══════════════════════════════════════════════════════════════════════════════════════════════════╝

  Row │ Test / Attribute                  │ Status │ Key gap or asset note
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
   1  │ Assay / related substances (HPLC) │   ■    │ 3× 1260 HPLC-DAD; methods need semisolid
      │                                   │        │ extraction validation; [verified-secondary]
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
   2  │ Identity (MS confirmation)        │   ■    │ LC-MS/MS available; second MS TBD
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
   3  │ Preservative assay                │   ■    │ 1260 HPLC-DAD; UV chromophore required
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
   4  │ pH                                │   ◑    │ Need spear / flat-tip electrode for semisolids
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
   5  │ Viscosity / rheology              │   □    │ No viscometer or rheometer on site; outsource
      │                                   │        │ or purchase rotational viscometer (PDDM911)
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
   6  │ Microscopy (droplet size, crystal) │  □    │ No polarized-light microscope; outsource
      │                                   │        │ or purchase (Week 11 decision)
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
   7  │ Uniformity in containers          │   ■    │ HPLC assay with spatial sampling; balance
      │                                   │        │ needed (confirm presence, Week 3)
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
   8  │ Minimum fill / net weight         │   ◑    │ Top-loading balance needed; confirm tare
      │                                   │        │ capacity for tube packaging
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
   9  │ Specific gravity / density        │   ◑    │ Pycnometer or wt/gal cup; low cost addition
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
  10  │ Water content (Karl Fischer)      │   □    │ No KF on site; outsource chemistry lab
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
  11  │ Water activity (a_w, USP <1112>)  │   □    │ No a_w meter; purchase (Week 11) or outsource
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
  12  │ TAMC / TYMC (USP <61>)            │   □    │ BacT/ALERT is presence/absence only;
      │                                   │        │ contract micro lab required
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
  13  │ Specified organisms (USP <62>)    │   □    │ Same gap; contract micro lab
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
  14  │ Bcc (USP <60>)                    │   □    │ Requires BCSA selective media + ID method;
      │                                   │        │ contract micro lab with documented experience
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
  15  │ AET / preservative efficacy       │   □    │ USP <51> Category 2 log-reduction counts;
      │   (USP <51>)                      │        │ contract micro lab; BacT/ALERT excluded
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
  16  │ Residual solvents (USP <467>)     │   □    │ GC-HS required; outsource
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
  17  │ Elemental impurities (<232>/<233>) │  □    │ ICP-MS / ICP-OES required; outsource
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
  18  │ IVRT (Franz cells)                │   □    │ No Franz cells or diffusion apparatus;
      │                                   │        │ outsource to specialized lab
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
  19  │ Stability storage (ICH Q1A/Q1B)   │   □    │ No ICH chambers; outsource stability lab
 ─────┼───────────────────────────────────┼────────┼──────────────────────────────────────────────
  20  │ Leachables / cleaning residues    │   ◑    │ LC-MS/MS covers non-volatile leachables;
      │                                   │        │ volatile leachables need GC-MS (outsource)
 ─────┴───────────────────────────────────┴────────┴──────────────────────────────────────────────

  SUMMARY:   ■ IN-HOUSE NOW: rows 1, 2, 3, 7
             ◑ MINOR ADDITION: rows 4, 8, 9, 20
             □ OUTSOURCE: rows 5, 6, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19

  [All status tags = verified-secondary; confirm against purchased assets in Week 3 walk-down]

Maps all twenty release and characterization tests against the current Sarasota asset inventory, revealing that four tests are ready, four need minor additions, and twelve require contract laboratories or future capital purchases.

---

Diagram 4: Intake-to-Release Dossier Architecture and Section Ownership

╔═══════════════════════════════════════════════════════════════════════════════════════════════╗
║                     INTAKE-TO-RELEASE DOSSIER — SECTION MAP                                   ║
║              Each section has an entry criterion, exit criterion, and owning course            ║
╚═══════════════════════════════════════════════════════════════════════════════════════════════╝

  ┌─────────────────────────────────────────────────────────────────────────────────────────┐
  │  INTAKE  (PDDM900)                                                                       │
  │  Dermatologist spec form — actives, concentrations, vehicle family, claims,              │
  │  intended package, intended seller, dermatologist sign-off                               │
  │  EXIT: classification gate passed; no stop triggers                                      │
  └───────────────────────────────────┬─────────────────────────────────────────────────────┘
                                       │
                                       ↓
  ┌────────────────────────────────────────────────────────────────────────────────────────┐
  │  SECTION 1 — CLASSIFICATION  (PDDM901)                                                  │
  │  Monograph match, drug vs cosmetic vs drug-cosmetic, OTC conditions verified,            │
  │  applicability register rows triggered                                                   │
  └───────────────────────────────────┬────────────────────────────────────────────────────┘
                                       │
                          ┌────────────┴────────────┐
                          ↓                         ↓
  ┌───────────────────────────────┐   ┌──────────────────────────────────────────────────┐
  │  SECTION 2 — MATERIALS        │   │  SECTION 3 — FORMULATION & OPERATING ENVELOPE    │
  │  (PDDM902)                    │   │  (PDDM903)                                        │
  │  Component qualification,     │   │  QbD design space, CPPs, CQAs,                    │
  │  DEG/EG testing, supplier     │   │  bench-scale procedure, extraction validation     │
  │  qualification, RStan qual    │   │  for HPLC assay of semisolid matrix               │
  └───────────────────────────────┘   └──────────────────────────────────────────────────┘
                          │                         │
                          └────────────┬────────────┘
                                       ↓
  ┌────────────────────────────────────────────────────────────────────────────────────────┐
  │  SECTION 4 — ENVIRONMENT & WATER  (PDDM911)                                             │
  │  Microbial risk of water-containing formulation, PW system gap,                          │
  │  environmental monitoring, HVAC GMP zones                                                │
  └───────────────────────────────────┬────────────────────────────────────────────────────┘
                                       │
                          ┌────────────┴────────────┐
                          ↓                         ↓
  ┌───────────────────────────────┐   ┌──────────────────────────────────────────────────┐
  │  SECTION 5 — RELEASE TESTING  │   │  SECTION 6 — MICROBIOLOGY                        │
  │  (PDDM912)                    │   │  (PDDM913)                                        │
  │  Specification, methods, lab  │   │  <61>/<62>/<60>/<51>, contract lab               │
  │  assignments, own vs outsource│   │  qualification, BacT/ALERT scope limits           │
  │  economics                    │   │                                                    │
  └───────────────────────────────┘   └──────────────────────────────────────────────────┘
                          │                         │
                          └────────────┬────────────┘
                                       ↓
  ┌────────────────────────────────────────────────────────────────────────────────────────┐
  │  SECTION 7 — COMPLIANCE & QMS DELTAS  (PDDM914)                                        │
  │  SOPs added/modified vs PDQC baseline, OOS workflow for semisolid viscosity and micro,  │
  │  applicability register version with all rows closed or escalated                       │
  └───────────────────────────────────┬────────────────────────────────────────────────────┘
                                       │
             ┌─────────────────────────┼──────────────────────────┐
             ↓                         ↓                          ↓
  ┌────────────────────┐  ┌─────────────────────────┐  ┌───────────────────────────────┐
  │  SECTION 8         │  │  SECTION 9              │  │  SECTION 10                   │
  │  PROCESS & PV      │  │  CLEANING               │  │  PACKAGING & LABELING         │
  │  (PDDM921)         │  │  (PDDM922)              │  │  (PDDM923)                    │
  │  CMO process       │  │  Shared-facility cross- │  │  NDC, Drug Facts, tamper       │
  │  validation,       │  │  contamination, OEL for │  │  evidence (or exemption),      │
  │  batch records     │  │  API-active semisolids  │  │  CR packaging triggers,        │
  │                    │  │                         │  │  201.66, 201.1                 │
  └────────────────────┘  └─────────────────────────┘  └───────────────────────────────┘
             │                         │                          │
             └─────────────────────────┼──────────────────────────┘
                                       ↓
  ┌────────────────────────────────────────────────────────────────────────────────────────┐
  │  SECTION 11 — STABILITY & IVRT  (PDDM924)                                              │
  │  ICH Q1A(R2) conditions incl. §2.2.7.3 semi-permeable, photostability,                 │
  │  IVRT method qualification, IVRT as stability discriminator                             │
  └───────────────────────────────────┬────────────────────────────────────────────────────┘
                                       │
                                       ↓
  ┌────────────────────────────────────────────────────────────────────────────────────────┐
  │  TECH-TRANSFER GATE  (PDDM925)                                                          │
  │  All sections closed, no [unverified] rows blocking, CMO quality agreement signed,       │
  │  batch record approved, release specification signed by QU head                         │
  └───────────────────────────────────┬────────────────────────────────────────────────────┘
                                       │
                                       ↓
  ╔════════════════════════════════════════════════════════════════════════════════════════╗
  ║                 PDDM999 CAPSTONE DEFENSE — full dossier presented to                   ║
  ║                 panel acting as QU head + regulatory counsel                           ║
  ╚════════════════════════════════════════════════════════════════════════════════════════╝

Shows how the thirteen dossier sections flow sequentially and in parallel from the dermatologist intake form through to the tech-transfer gate and capstone defense, with each section's owning course identified.

---

Diagram 5: Florida Permit and Federal Registration Trigger Map

╔════════════════════════════════════════════════════════════════════════════════════════════╗
║        FLORIDA §499 PERMIT + FEDERAL REGISTRATION TRIGGER MAP                              ║
║        Peptide Partners, Sarasota, FL — PDDM900 Week 5 & 6 Analysis                       ║
╚════════════════════════════════════════════════════════════════════════════════════════════╝

  ACTIVITY AT SITE ──────────────────────────────────────────────────────────────────────────

  Manufacture OTC semisolids                   ──→  Florida §499.01(2)(n)  OTC Drug Mfr Permit
  (creams, ointments, lotions, gels)                 Fee: $300–$400/yr [§499.041]
                                                     Must meet state + federal cGMP
                                                     Biennial product registration §499.015

  Possess/purchase Rx drugs at same site       ──→  EITHER: separate §499.01(2)(a) Rx Mfr Permit
  (incl. some research peptides)                     OR: segregate / transfer materials
                                                     [COUNSEL QUESTION — unverified]

  Make pure cosmetics at same site             ──→  Florida §499.01(2)(p) Cosmetic Mfr Permit
  (no drug active, annual sales >$25k)               OR: exemption if sales ≤$25k or relabel only
                                                     MoCRA §364c: register within 60 days
                                                     §364h small-business exemption may apply

  ─────────────────────────────────────────────────────────────────────────────────────────────

  FEDERAL REGISTRATION & LISTING TRIGGERS  (21 CFR 207)

  ┌──────────────────────────────────────────────────────────────────────────────────┐
  │  Start manufacturing operations                                                   │
  │       ↓                                                                           │
  │  Register within 5 calendar days  (21 CFR 207.17)                                │
  │  Use site-specific DUNS (not corporate HQ DUNS)                                   │
  │  Submit in SPL format                                                             │
  │       ↓                                                                           │
  │  List every commercial drug product  (21 CFR 207.41)                              │
  │  Update registration annually Oct 1–Dec 31  (21 CFR 207.21)                      │
  └──────────────────────────────────────────────────────────────────────────────────┘

  NDC LABELER CODE
  ┌──────────────────────────────────────────────────────────────────────────────────┐
  │  Owned by the MARKETING FIRM (labeler), not the contract manufacturer            │
  │  'Distributed by' arrangement: 21 CFR 201.1 and 207.1                            │
  │  12-digit NDC final rule effective 2033-03-07 [flag for current confirmation]    │
  └──────────────────────────────────────────────────────────────────────────────────┘

  OMUFA FACILITY FEE CLASSIFICATION  (21 USC 379j-71 / 379j-72)
  ┌─────────────────────────────────┬───────────────────────────────────────────────┐
  │  MDF (manufacturing facility)   │  Owner or affiliate sells directly to market  │
  │  FY2027: $47,891                │  50% due 2026-10-01; 50% due 2027-02-01       │
  ├─────────────────────────────────┼───────────────────────────────────────────────┤
  │  CMO rate                       │  Manufacturer does NOT sell directly          │
  │  FY2027: $31,927                │  Same payment schedule                        │
  ├─────────────────────────────────┼───────────────────────────────────────────────┤
  │  ARREARS CONSEQUENCE            │  Every product from the facility is           │
  │  (§502(ff))                     │  MISBRANDED — products cannot be marketed     │
  └─────────────────────────────────┴───────────────────────────────────────────────┘

  MoCRA DRUG EXEMPTION
  ┌──────────────────────────────────────────────────────────────────────────────────┐
  │  Products regulated as drugs under FD&C Act → §364i exempts from MoCRA §364c   │
  │  facility registration. OTC drug products fall here.                             │
  │  BUT: if ANY pure cosmetic is made at same address → §364c is triggered.         │
  └──────────────────────────────────────────────────────────────────────────────────┘

  [verified-primary: 21 CFR 207; 21 USC 379j-71/72; 21 USC 364c/364h/364i; §499.01(2)]
  [FY2027 fee figures: verified-secondary — confirm on FDA OMUFA fee schedule page]

Integrates Florida §499 permit requirements, federal FDA registration and listing triggers, NDC labeler code ownership, OMUFA fee classification with misbranding consequences, and the MoCRA cosmetic exemption logic into a single one-page regulatory map.

---

Key Takeaways

  1. The classification gate is a hard stop, not a soft filter. If an active does not appear in an OTC Final Monograph or §505G order — or if the formula contains hydroquinone or a corticosteroid above hydrocortisone 1% — the dossier terminates at intake. No amount of formulation work downstream can rescue a product that fails the classification test. This is the most important lesson from the PDDM900 scope boundary, because the formulator (not the regulator) initiates the work and may not fully understand what "monograph conforming" requires under 21 CFR 330.1. Every general condition in 330.1 — labeling, testing, manufacturing under cGMP — must be satisfied simultaneously, not just ingredient identity.
  2. The BacT/ALERT system cannot satisfy USP <61>, <62>, or <51> — this is not a configuration problem, it is a physics problem. BacT/ALERT detects CO₂ evolution as a qualitative presence/absence signal. USP <61> TAMC and TYMC require enumeration of colonies per gram. USP <51> Category 2 preservative efficacy requires log-reduction counts at specific time points (≥2.0 log bacterial reduction at 14 days; no increase to 28 days). A CO₂ detector cannot count colonies or quantify log reductions. No software update or protocol modification will bridge this gap. The BacT/ALERT is a valuable future asset for sterile peptide sterility testing under <71> — but for the current nonsterile semisolid program, its role is zero, and contract microbiology is mandatory from day one.
  3. Water-containing semisolids carry a microbial risk that anhydrous ointments do not, and this difference drives an entirely different regulatory and testing posture. An anhydrous petrolatum-based ointment has water activity (a_w) below 0.6 and will not support microbial growth even without a preservative. An o/w cream at 70% water phase has a_w near 1.0 and is a rich microbial growth medium during manufacture, filling, and in-use consumer contamination. USP <1111> cutaneous criteria (TAMC ≤10² cfu/g; TYMC ≤10¹ cfu/g; absence of S. aureus and P. aeruginosa in 1 g) apply because of this risk. The practical implication: every water-containing formula in the intake dossier immediately triggers the full micro test matrix, the preservative efficacy (AET) test, and the water-activity measurement row — while an anhydrous formula may eliminate or substantially reduce those rows.
  4. The identity test on every component lot (21 CFR 211.84(d)) is non-delegable and cannot be replaced by a certificate of analysis alone. This is one of the most frequently cited cGMP violations in FDA warning letters to topical product manufacturers. The regulation requires the QC unit to test each component lot for identity using a scientifically valid method — a CoA from the supplier is corroborating data, not identity testing. For high-risk components such as glycerin, propylene glycol, and sorbitol, FDA guidance (May 2023) further requires a limit test for diethylene glycol (DEG) and ethylene glycol (EG) at ≤0.10% per shipment lot, not per supplier approval. This is a concrete, quantitative, enforceable requirement that must appear as a row in both the applicability register and the component release procedure.
  5. Carbomer-containing formulas carry a specific benzene risk that requires GC-MS or GC-HS capability — which Peptide Partners does not currently have. FDA's December 2023 guidance on reformulating drug products containing carbomers manufactured with benzene requires testing to confirm benzene levels at or below 2 ppm. Carbomer synthesis historically used benzene as a solvent, and residual benzene is classified as a Class 1 solvent (limit 2 ppm, USP <467>) and a known human carcinogen. Any formula in the intake dossier that specifies a carbomers-based gel immediately places benzene screening on the outsource list, because <467> Class 1 screening requires GC-headspace methodology. A gel that looks analytically simple becomes analytically demanding at the component identity level.
  6. OMUFA facility-fee arrears turn every product from the site into a misbranded drug under FD&C Act §502(ff) — not just a compliance problem, a product status problem. This is a counterintuitive consequence. A product can be perfectly formulated, correctly labeled, and fully tested, and yet be legally misbranded simply because the manufacturing facility owner has not paid a fee. The arrears list is publicly posted; FDA can act on misbranding without any product quality defect. The practical implication for program launch: OMUFA fee payment must appear on the compliance calendar before the first commercial batch is released, with the 50%/50% payment schedule (Oct 1 / Feb 1) documented in the QMS. Whether Peptide Partners qualifies as MDF ($47,891 FY2027) or CMO ($31,927 FY2027) depends on whether the entity itself — or an affiliate — sells directly to the market.
  7. The semisolid spear electrode for pH measurement is not a minor accessory — it is the difference between a measurement and a failed measurement. Standard glass bulb pH electrodes require a liquid sample. Creams and ointments are semi-solid; pressing a standard electrode into them creates air gaps, poor contact, and drifting, irreproducible readings. A flat-membrane or spear-type electrode is specifically designed to penetrate the semi-solid surface and maintain junction contact. This matters for release testing (pH is a CQA for preservation, skin compatibility, and chemical stability of pH-sensitive actives) and for in-process control during manufacture. A missing spear electrode is not a paperwork gap — it means pH cannot be measured compliantly on semisolid matrices at Peptide Partners today. Row 4 on the test matrix is correctly scored as "minor addition needed."
  8. ICH Q1A(R2) §2.2.7.3 applies specifically to semi-permeable containers (laminate tubes, airless pumps) and introduces a low-humidity storage condition that no standard ICH chamber automatically includes. For products in semi-permeable packaging, a 5% weight loss from the nominal fill is defined as a "significant change" threshold. To detect this, accelerated stability must be run at low relative humidity (25°C/40% RH or 30°C/35% RH) — conditions not included in the standard 25°C/60% RH or 40°C/75% RH chambers. A 30g laminate tube filled with an o/w cream is the placeholder spec for the Week 13 dry run; that tube is semi-permeable, so this condition triggers automatically. This means when qualifying a contract stability lab, you must explicitly ask whether they operate low-RH chambers — many do not, and this gap would delay the entire stability program.
  9. The Florida §499.01(2)(n) OTC drug manufacturer permit prohibits possessing or purchasing prescription drugs at the same site, and some research peptides at Peptide Partners may qualify as prescription drugs under this prohibition. This is a permit-classification problem, not a safety problem. §499.01(2)(a) is required to hold Rx materials. The path forward is not to make a unilateral determination about which peptides are "prescription drugs" — that question requires legal counsel, because the classification depends on the specific compound's regulatory status, not just its research label. What PDDM900 requires Skipper to do is frame the segregation options precisely (separate legal entity, separate premises, Rx permit, transfer, reclassification as reference standards) with the evidence requirement for each option, so counsel can advise efficiently. The program cannot launch until this question is resolved with a documented legal determination.
  10. 21 CFR 211.22 Quality Unit duties cannot be delegated to a CMO — the brand owner retains QU responsibility even when all manufacturing is outsourced. This is one of the most consequential principles in contract pharmaceutical manufacturing, and it was the central lesson in the Columbia Cosmetics warning letter. The CMO operates under its own QU for its cGMP compliance, but the brand owner's QU must independently review batch records, approve specifications, and make release decisions for its products. The quality agreement (21 CFR §211.34 consultant records; FDA quality agreement guidance) defines responsibility splits but cannot strip the brand owner of QU authority. In practical terms: Larissa (or a future QU head) must be able to review a CMO batch record and make an independent release decision — she cannot simply accept the CMO's release as her own.
  11. The confidence-tag discipline ([verified-primary]/[verified-secondary]/[unverified]) is not a formatting convention — it is a data-integrity control that determines whether a gate can close. An [unverified] row in the applicability register means the underlying regulatory requirement has not been confirmed from a primary source. It is a mandatory rule of this program that [unverified] rows cannot close a gate. This prevents the program from advancing based on assumptions that turn out to be wrong — for example, an [unverified] assumption about the Florida DBPR pre-permit inspection process that turns out to require additional SOPs before the site can operate. The connection to what Skipper knows from PDQC801 is direct: ALCOA+ (attributable, legible, contemporaneous, original, accurate, plus complete, consistent, enduring, available) applies not just to analytical data but to regulatory intelligence. Citing a secondary source for a compliance trigger when a primary source is accessible is an ALCOA violation in spirit.
  12. The NDC labeler code is owned by the marketing firm (labeler), not the contract manufacturer — and the 12-digit NDC final rule takes effect 2033-03-07, affecting all product labeling and database submissions. Under the current 10-digit system, NDC codes have three segments (labeler/product/package) in formats like 5-4-1 or 4-4-2. The 2033 final rule standardizes to a uniform 12-digit format. For a program launching now with products intended to have market lives extending past 2033, labeling systems and database submissions must be designed with this transition in mind. The practical implication: the intake form must capture the intended labeler (marketing firm) and their NDC labeler code at the time of intake, because this determines how the product is listed in SPL format under 21 CFR 207.41 and how Drug Facts label copy is structured under 21 CFR 201.66.
  13. Burkholderia cepacia complex (Bcc) contamination of water systems at contract manufacturers is a recurring FDA enforcement theme in 2025 warning letters, and it must be an explicit screening criterion in CMO qualification. Bcc is an opportunistic pathogen capable of surviving in water systems, disinfectants, and even some preservative solutions. It is particularly dangerous in immunocompromised patients and has caused product recalls. FDA warning letters to Columbia, Libby, and Strukmyer in 2025 all cited water-system microbiological failures. When qualifying a CMO for semisolid manufacture, the pre-qualification questionnaire must explicitly ask: what selective media does the lab use for Bcc detection (BCSA — Burkholderia cepacia selective agar), what identification method (MALDI-TOF or 16S rRNA sequencing), and what is the environmental monitoring water-system isolate history? A CMO that cannot answer these questions specifically should be screened out before on-site audit resources are committed.
  14. The "§211.137(h) expiry discretion" provision does not eliminate the §211.166 stability requirement — it is a narrow enforcement policy for OTC products without an established expiry date, not a regulatory exemption from stability testing. This is a subtle but critical distinction. Some OTC products have historically been marketed without printed expiry dates under discretionary FDA enforcement policy (§211.137(h)). But §211.166 requires that a manufacturer have stability data supporting whatever shelf life is claimed or implied — even if no date is printed on the label. A product marketed as "does not expire" or with no date still needs a stability program. In the applicability register, §211.137(h) and §211.166 must appear as separate rows with separate evidence requirements, and they cannot be collapsed into a single row with a note that "no expiry date = no stability needed." That interpretation would be wrong and would fail in an FDA inspection.
---

References

  1. Sharp, J., Good Pharmaceutical Manufacturing Practice: Rationale and Compliance, 1st ed. CRC Press, 2005.
  2. Sheskey, P.J.; Hancock, B.C.; Moss, G.P.; Goldfarb, D.J. (eds.), Handbook of Pharmaceutical Excipients, 9th ed. (verify current edition). Pharmaceutical Press / American Pharmacists Association.
  3. Lieberman, H.A.; Rieger, M.M.; Banker, G.S. (eds.), Pharmaceutical Dosage Forms: Disperse Systems, 2nd ed. Marcel Dekker.
  4. Chang, R.K.; Raw, A.; Lionberger, R.; Yu, L., 'Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products,' AAPS Journal, 2013. DOI: 10.1208/s12248-012-9411-0
  5. Chang, R.K.; Raw, A.; Lionberger, R.; Yu, L., 'Generic development of topical dermatologic products, Part II: quality by design for topical semisolid products,' AAPS Journal, 2013. DOI: 10.1208/s12248-013-9472-8
  6. Buhse, L.; Kolinski, R.; Westenberger, B.; et al., 'Topical drug classification,' International Journal of Pharmaceutics, 2005. DOI: 10.1016/j.ijpharm.2005.01.032
  7. U.S. Food and Drug Administration, Guidance for Industry: Reformulating Drug Products That Contain Carbomers Manufactured With Benzene. FDA, December 2023. [Verify current version at FDA.gov]
  8. U.S. Food and Drug Administration, Guidance for Industry: Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol, Rev. 1. FDA, May 2023. [Verify current version at FDA.gov]
  9. U.S. Food and Drug Administration, Microbiological Quality Considerations in Non-Sterile Drug Manufacturing (draft guidance). FDA, September 2021. [Verify current version at FDA.gov]
  10. U.S. Food and Drug Administration, Contract Manufacturing Arrangements for Drugs: Quality Agreements (guidance for industry). FDA. [Verify current version and date at FDA.gov]
  11. International Council for Harmonisation, ICH Q1A(R2): Stability Testing of New Drug Substances and Products, 2003. [Verify for ICH Q1 consolidated revision status]
  12. International Council for Harmonisation, ICH Q1B: Stability Testing: Photostability Testing of New Drug Substances and Products, 1996. [Verify current status]
  13. International Council for Harmonisation, ICH Q3D(R2): Guideline for Elemental Impurities, 2022. Appendix 5 (cutaneous route PDEs). [Verify current edition]
  14. United States Pharmacopeial Convention, USP General Chapters: <3> Topical and Transdermal Drug Products — Product Quality Tests; <51> Antimicrobial Effectiveness Testing; <60> Tests for Burkholderia cepacia Complex; <61> Microbiological Examination of Nonsterile Products — Microbial Enumeration Tests; <62> Microbiological Examination of Nonsterile Products — Tests for Specified Microorganisms; <232> Elemental Impurities — Limits; <233> Elemental Impurities — Procedures; <467> Residual Solvents; <645> Water Conductivity; <912> Rotational Rheometry; <921> Water Determination; <1111> Microbiological Examination of Nonsterile Products — Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use; <1112> Application of Water Activity Determination to Nonsterile Pharmaceutical Products; <1223> Validation of Alternative Microbiological Methods. United States Pharmacopeia. [All chapters: verify against current official USP edition]
  15. U.S. Code of Federal Regulations, Title 21: §201.1 (Name and place of business); §201.66 (Drug Facts labeling); §207.1, 207.17, 207.21, 207.33, 207.41 (Registration and listing, NDC); §211.22 (Quality Unit); §211.34 (Consultants); §211.84(d) (Component testing); §211.100(a) (Written procedures); §211.113(a) (Microbial contamination control); §211.132 (Tamper-evident packaging); §211.137(h) (Expiration dating); §211.165(b) (Testing and release); §211.166 (Stability testing); §211.192 (Production record review); §330.1 (OTC drug products — general conditions). [All CFR citations: verify against current annual CFR edition]
  16. U.S. Federal Food, Drug, and Cosmetic Act (FD&C Act), as amended: §502(ff) (Misbranding — OMUFA arrears); §505G (21 USC 355h, OTC monograph reform); §760 (21 USC 379aa, nonprescription serious adverse event reporting); §§379j-71/379j-72 (21 USC, OMUFA facility fees); §§364c, 364h, 364i (21 USC, MoCRA cosmetic facility registration, small-business and drug exemptions); §§353a/353b (21 USC, compounding exemptions — contrast only). [Verify current codification]
  17. Florida Statutes, Chapter 499: §499.003 (definition of manufacture, including compounding); §499.01(2)(a) (prescription drug manufacturer permit); §499.01(2)(n) (OTC drug manufacturer permit); §499.01(2)(p) (cosmetic manufacturer permit); §499.015 (biennial drug product registration); §499.041 (permit fees). [Verify current Florida Statutes at leg.state.fl.us]
  18. Florida Administrative Code, Rule 61N-1. [Unverified — verify current rule text and applicability at flrules.org; flag as DBPR field-research task]
  19. Florida Statutes §465.003 and Florida Administrative Code Rule 64B16-27.700 (Board of Pharmacy compounding — contrast only; rule amended 2026-08-03; verify current text at flrules.org).
  20. 16 CFR Part 1700.14, Poison Prevention Packaging Act: Substances Requiring Special Packaging. Consumer Product Safety Commission. [Verify current list of substances requiring child-resistant packaging]
  21. U.S. Food and Drug Administration, OMUFA Facility Fee Schedule FY2027. [Verify current fee amounts and payment schedule at FDA.gov/industry/user-fees/over-counter-monograph-drug-product-fees]